OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME

Abstract: For use in controlling biologic functions in an organism, a stabilized oligonucleotide, preferably in a phosphotriester form, having a base sequence substantially complementary to a portion of messenger ribonucleic acid coding for a biological component, such as a protein, of the organism. The oligonucleotide has about fourteen bases or more, such as twenty-three bases, and can be a deoxyribonucleotide. The oligonucleotide sequence can be derived from the organism's ribonucleic or deoxyribonucleic acid that codes for a vital protein, and can be synthesized in bulk either chemically or by insertion into a plasmid.

Description: OLIGONUC EOTIDΞ THERAPEUTIC AGENT AND METHODS OF MAKING SAME BACKGROUND OF THE INVENTION This invention relates generally to controlling biologic functions, such as for antibiotic purposes, and more particularly, to utilizing hybridization techniques of the type having messenger ribonucleic acid attached to oligonucleotides for ___ vivo protein synthesis regula¬ tion.. In the field of pharmacology, the use of therapeutic agents has long been recognized as an effec- ti e way to control diseases. Such agents are often used in treating bacterial or viral infections, chemical imbalances and the like to cure, or at least mitigate, the diseased state. Although researchers occasionally discover new- therapeutic agents after major break- thrσughs have elucidated the molecular basis of a dis¬ ease, more often they must rely on observing for anti¬ biosis- or modifying the chemical structures of func¬ tionally related chemicals. With respect to antibiotic agents, some are quite effective at the outset, but over time many organ¬ isms become resistant or totally immune to their action. Additionally, very few effective anti-viral agents have ever been developed, and without explicit, detailed knowledge of an infecting organism's physiology, the development of new operative agents remains haphazard. Thus, there exists a definite need for a methodology enabling the systematic design of new anti¬ biotics and other therapeutic agents that is versatile and inexpensive, yet produces agents that are both extremely specific and effective. The present invention fulfills these needs. SUMMARY OF THE INVENTION The present invention provides a methodology of identifying and constructing therapeutic and other agencs for use in living organisms that substantially reduces the uncertainty surrounding the development of new antagonists, significantly increasing the scope of mat ria medica. Moreover, the agent construction of the present invention lends itself readily to simple manufac¬ ture * even in large quantities, is extremely effective in use, and attains its improved results without undue cross-reactions. In a presently preferred embodiment of the invention, by way of example and not necessarily by way of limitation, a stabilized oligonucieotide, preferably in a phosphotriester form, is provided having a base sequence substantially complementary to a portion of messeαger ribonucleic acid coding for a biological component of an organism. Due to the complementary nature of the oligonucieotide and the messenger ribo- nucleic acid, the two components can readily hybridize under appropriate conditions to control synthesis of :_ιs organism's biological component and, if the protein^ is vital to the organism's viability, to act as an anti¬ biotic. A method, in accordance with the present invention, of developing therapeutic agents may typically include the steps of: providing a base sequence of an organism's nucleic acid that contains at least a portion of the genetic information for a biological component of the organism, and synthesizing an oligonucieotide the sequence of which is derived from the base sequence, for OMPI subsequent hybridization with the messenger ribonucleic acid specific for the biological component. The biologi¬ cal component may be a vital protein, or simply a hormone such as the gonadotropin, follicle stimulating hormone. The order of the base sequence may be determined from deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) , preferably messenger ribonucleic acid (mRNA) . Alterna¬ tively, the desired oligonucieotide base sequence may be determined from the biological component's sequence, as when the biological component is a protein. The pre¬ ferred oligonucieotide has a minimum of about fourteen or more bases, such as about twenty-three bases, and for increased stability, may be transformed to a more stable form, such as a phosphotriester form, to inhibit degrada- tioπ during use. To produce . large quantities of the oligonucieo¬ tide, it may be synthesized chemically, such as in automated machines, or inserted into a plasmid, such as pBR322, for cloning. The plasmid insertion may be accomplished with linker base sequences, such as GATTC- GAATC or CTAAGCTTAG, which are susceptible to degradation by Hind III restrictive nuclease or Alu I restriction nuclease. When the order of the base sequence has not been determined, the base sequence can.be cloned and then cross-hybridized against messenger ribonucleic acid from the other sources to remove base sequences non¬ specific to the target. Another aspect of the present invention is a method of selectively controlling activity of one or more biological components in a cell without substantially interfering with the activity of other biological compo¬ nents in the cell. The method includes the steps of OMPI forming an oligonucieotide having a base sequence sub¬ stantially complementary to a portion of RNA coding for the specific biological component, and introducing the oligonucieotide into the cell for hybridisation ith the selected mRNA. This causes blocking of the transla¬ tion of the mRNA into protein. The oligonucieotide may have at least about fourteen bases or more, such as about twenty—three bases. The target mRNA can code for a protein, such as the hormone, follicle stimulating hormone. This hormone has an alpha and beta chain, and the oligonucieotide should be specific for the mRNA coding for the beta chain, to avoid cross-reacting with other gonacatropin mRNA. A suitable oligonucieotide base sequence would be λCCACGCGR,CCR 2 ATGACGATGTG, wherein K j . is G" or T and R 2 is also G or T. In accordance with another aspect of the present invention, a method is provided for inhibiting the infection of a host organism by a foreign organism. This method entails isolating a base sequence containing at least a portion of the genetic information coding for a vital protein from the foreign organism's nucleic acid; synthesizing an oliconucieotide, the order of which is derived from the base sequence and substantially comple¬ mentary to the messenger ribonucleic acid coding for the protein; and treating the foreign organism with an effective amount of the oligonucieotide to hybridize with a portion of the messenger ribonucleic acid and block translation of the protein. The- oligonucieotide, which can be a deoxyribonucleotide, can be transformed to a more stable form, such as a phosphotriester form- to inhibit degradation, and the order of the sequence determined prior to its synthesis. Further, to increase the oligonucieotide's specificity, it may be cross-hybri- dized against mRNA from different organisms, such as the host organism, to remove non-unique oligonucieotide seσuences. It will be appreciated from the foregoing that the present invention satisfies a long existing need for improved methods of developing therapeutic agents for use in living organisms, and represents a significant advance over previously available methods, principally because it is very versatile, and yet provides a very specific agent against a biological component. Other aspects and advantages of the invention will become apparent from the following more detailed description taken in conjunction wit the accompanying drawings. BRIEF -DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow diagram showing the central dogma of molecular bioI©σy; FIG. 2 is a flow diagram showing normal trans¬ lation of messenger ribonucleic acid (mRNA) into T 5 protein, as well as 3= synthetic oligonucieotide of the present invention blodcing translation of the T protein; FIG.3 is a list of the -/iral d oxyribonucleic acid (DNA) code specific for SV-40 T protein, and the related mRNA and oligos-α leotide: iα- FIG.4 is a Sow diagram showing the construc¬ tion of high yield plasmids containing the T protein oligonucieotide; FIG.5 is a flow diagram showing the use of restriction nucleases to cleave the plasmids to give * a 15 purified T protein oligonucieotide; FIG. 6 is a How diagram showing the treatment of a DNA sequence to form DNA polyphosphotriesters; and 20 FIG. 7 is a chart showing the partial amino acid sequence of follicle stimulating hormone, as well as the predicted mRNA sequence and related oligonucieotide family. OMPI DETAILED DESCRIPTION OF THE INVENTION Referring now to the drawings, and particularly to FIGS. 1 and 2, there is shown the so-called "central dogma" of the molecular biology of life. Basically, it is now accepted that deoxyribonucleic acid (DNA) carries the genetic code. for almost all living organisms. The code exists in the form of an organized sequence of four nucleotide bases attached to a phosphorylated, deoxyri- bose sugar backbone. Generally, DNA exists in the form of a double strand helix formed of two oppositely direc¬ ted, strands, which are held together in an opposing manner by various weak forces. A primary constituent of these weak forces are the so-called hydrogen bonds that exist between nucleo- tides on the opposing strands. The four bases, adenine (A),, cytosine (C) , guanine (G) , and thymine (T) , form hydrogen bonds generally in only one fashion: A with T and C with G. Thus,- by knowing the sequence o one strand, the sequence of the second strand can be readily determined. Another aspect of the central dogma is that proteins are produced indirectly from the DNA strand, through messenger ribonucleic acid (mRNA) . Apparently, mRNA, which has the same structure as single stranded DNA except with a ribose backbone and with uracil (U) replac¬ ing thymine, is transcribed directly from one DNA strand and has an essentially opposite base sequence, i.e., if a DNA strand sequence is 5' ACGT 3' the transcribed mRNA sequence is 3'...UGCA...5'. An additional aspect of the central dogma rel a te s to th e trans l a t i on o f mRNA i n to pr o t e i n s . OMPI - Briefly, excluding initiation sites and the like, each three nucleotide base grouping (triplet code) codes for one amino acid of a protein. Therefore, by knowing the mRNA sequence of a protein, its amino acid sequence can Generally be determined- However f the reverse is net true, that is, knowing the amino acid sequence does not guarantee precise knowledge of the mRNA sequence. Tills stems from the fact that there exist 64 (4 ) possible triplet codes, yet there exists only about twenty amino acids, allowing some amino acids to have multiple triplet ccdes„ The similarity in the structure of DNA and mRNA strands creates interesting effects. Most notably, if complementary DNA and SNA strands exist contemporaneously in a solution ,- under certain established conditions the strands can anneal, forming hybrids. One important factor in proper annealing is the melting temperature, which can be calculated according to Britten et al , Methods of Enzyme logy 29:363 (1974). In. accordance with the present invention, a synthetic oligonucieotide having a base sequence capable of substantially matching that of a chosen mRNA is provided for hydridizatiσn with that mRNA. Once such a • hybrid exists, the translation of the mRNA into protein becomes significantly inhibited. If the inhibited protein is vital to an organism's survival, the organ¬ ism's viability, i.e., either growth or continued life, is jeopardized. Importantly, the oligonucieotide can be designed specifically for the mRNA coding for just one protein, and should not cross-react with mRNA for other proteins. OMPI The method of developing the oligonucieotide entails basically two steps. As described more fully below, a possible first step is to determine the appro¬ priate sequence of the mRNA specific for the protein to be inhibited, and a second step is to manufacture an oligonucieotide complementary to the mRNA. Once made, the oligonucieotide can be treated into a phospho- form for increased stability. A variety of techniques exists for determining nucleic acid base sequences. In many instances the sequence of the mRNA or the gene have been determined and published in the biochemical literature. In fact, researchers have determined the complete nucleotide sequence for the SV— 40 virus (Reddy et al , Science 200:494 (1978)) * . As is well known, an alternative method entail ' s isolating and purifying mRNA in sufficient quantities to permit sequencing studies, but this can prove difficult due to the relative instability and, in some cases,, extreme rarity of many mRNA sequences. Still another method for determining nucleic acid base sequences requires resolving the amino acid sequence from the target protein. After determining the amino acid sequence of the target protein in purified form, a sequential degradation utilizing commercially available protein sequences (e.g. from Beckman Instru¬ ments, Fullerton, California) can be used to provide the amino acid sequence. Once this has been obtained, knowledge of the triplet code can be applied to give prospective base sequences. An example of such a process for the hormone glucagon can be found in Tullis et al , Biochemical and Biophysical Research Communications 93:941 (1980). Once the sequence of -the appropriate nucleic acid and the desired mRNA sequence have been determined, an oligonucieotide, such as deoxyribonucleotide, comple¬ mentary to the mRNA can be constructed. A number of synthetic techniques are known, mtst typical is the diester approach described by Agarwal et al , Nature 227r 27 (1970) , and oligonucieotide synthesizers may be purchased commercially from Vega Biochemicals, P.O. Box 11648,. Tucson, Arizona and Biologicals, Inc., Toronto, Canada. If the desired oligonucieotide sequence is unknown, a suitable oligonucieotide . can be prepared as follows. After isolating mRNA from a target organism, multiple copies are made, preferably in the form of DNA, so-called copy DNA (cDNA) . This cDNA is then cross- hybridized against. mRNA isolated from other organisms, and any cDNA hybridizing is removed. The remaining cDNA is specific only to the target organism, and can serve as the therapeutic agent. In order to obtain a high degree of speci¬ ficity,, an oligomer of about fourteen or more residues can be constructed. Although shorter sequences will work r longer sequences provide higher specificity. This can readily be seen mathematically. Whereas a ten unit polymer chosen from four bases can have 4 (1,048,576) random combinations, a 20-unιt polymer has 4 20 random 12 combinations, which equals 1.09 x lϋ (1,090,000,000, 000) . In spite of the added difficulty in making oligαnucleotides of twenty units in comparison to ten bases, it is warranted because the exponential increase - II - in complexity reduces undesirable cross-reactivity. It has been estimated that a mammalian cell contains about g 2x10 nucleotides of RNA complexity or, in other words, approximately 200 million nucleotides of unique sequence 5 mRNA, which is equivalent to about 30,000 mRNA sequences. The probability that one of those sequences contains a randomly chosen 20-unit polymer is approxi ately one in fifty—five hundred. In comparison, a ten-unit polymer has about a one hundred and ninety to one chance for 0 random cross—reaction. The present invention is illustrated by, but .not limited to", the following examples. EXAMPLE I SV-40 virus manufactures a vital protein 5 commonly known as the rt T protein" or n T antigen protein". As noted earlier, the complete genetic code for the SV-40 virus has been determined, and it is known that residues 5091 tc 5071 on the viral genome code for a portion of the T protein mRNA. The sequence of these residues, the Q viral T protein mRNA sequence, and the designed T protein specific oligonucieotide are shown in Fig. 3. In this case, the T protein specific oligonucieotide is comple¬ mentary to the viral T protein mRNA, and identical to the portion of the viral DNA code. Prior to testing the effectiveness of the T protein specific oligonucieotide j-n vivo, the oligonuc¬ ieotide can be mixed with total mRNA from an organism to check for cross-reactivity. If it hybridizes, then a different portion of the viral genome coding for the T protein should be utilized. Otherwise, the oligonucieo¬ tide is ready for further testing. Further testing requires growth of 3-40 virus. For purposes of these experiments, SV-40 virus is grown and titered in African green monkey cells, such as the cell line BSC-1, according to Hopps et al, Journal of Immunology jJ1^ 16 (1963). The identity of t e virus can lie confirmed by the following methods: a) checking for tumor production after iπnoculation of the newborn hamsters with the virus; b) neutralization of the virus by anti-SV-40 aπtiserum; and c} reaction of the infected cells with anti—SV-40 T antigen directed antibodies prepared by standard techniques. The isolation of SV-40 mRNA can be accomplished as follows. Total RNA is first obtained by the guanidine hydrochloric acid extraction procedure using glassware previously baked and treated with diethylpyrocarbonate to remove traces of RNase as taught by Cox et al. Methods in Eπzymσlogy 12B?120 (1968) . The A+ RNA is isolated on oligσ-dTcelluIose, which can be obtained from Collabora¬ tive Research, Waltham ? Massachusetts, or P. » Biochem¬ icals,- Inc., Milwaukee, Wisconsin, utilizing the techni¬ que described by Bantle et al. Analytical Biochemistry 72;-413 (1976) . The RNA fractions are assayed for purity and intactness by electropheresis according to the method described in Bailey et al. Analytical Biochemistry 70:75 (1976). Also, the RNA can be assayed for translatability in the wheat embryo _in_ vitro system described in Marcus, et ai, Methods in Ξnzymology: 3_0_-:749 (1974). The in vitro translation products are monitored on sodium lauryl sulphate 9% polyacrylamide gels as described in Laemmeli, Nature 227:680 (1970). OMPI This purified A+ mRNA containing the viral mRNA sequences can hybridize to the synthetic oligo¬ nucieotide at 37 C in 0.5 M sodium phosphate buffer, pH 6.8, containing 0.2% sodium lauryl sulphate. Solutions - containing about 1 g A+ mRNA and synthetic oligonucieo¬ tide at a concentration of about 100 ug/ml are heated to 100°C for 1-2 minutes, then cooled to 37°C and allowed to anneal. The extent of the hybridization reaction as a function of time may be monitored on a gel filtration column. Actually, while any theoretically suitable temperature may be used for the hybrid formation, tempera¬ tures ranging from 0°C to about 80°C provide for good hybridization, but preferred temperatures range from about 10°C to about 40°C. Generally, the optimal annealing temperature for the formation of specific hybrids is believed to be about 20°C to 25°C below their melting temperature. Synthetic oligonucleotides operating at 37.5°C should thus be designed on the basis of their base sequence and length, such that the melting temperature is between about 57 C and 62 C when tested under approximately physiological conditions. For hybridization testing the ratio of the synthetic oligonucieotide to its mRNA complement is generally about 30:1. Lower ratios are acceptable, however, sequences below about 3:1 can cause lower hybrid formation. Control reactions utilizing yeast RNA or globin mRNA can be used, and should show no detectable hybrids, indicating hybridization specificity only to SV-40 mRNA. Also, thermal denaturation profile studies and comparison of the kinetics of hybridization can confirm that the synthetic oligonucieotide reacts only with SV—40 mRNA sequences. Once it is shown that the oligonucieotide hybridises to the isolated SV-40 mRNA,. Π vitro transla¬ tion tests can be attempted utilizing the wheat embryo syste (described previously) to show that the hybrid is not translated. Basically, upon introduction of SV-40 mRNA into the wheat embryo system, the system produces large T antigen protein. However, when an equal amount or more of synthetic oligonucieotide is also added 0 to the system, T antigen protein synthesis can be sub¬ stantially inhibited, without interference with synthesis of other SV-40 proteins whose mRNA was also introduced. Testing of the oligonucieotide j Ln vivo can be accompIished_by adding the oligonucieotide to cultures of 5 cells infected with SV-40. Synthesis of T antigen protein should be inhibited signficantly in about six hours, and SV-40 growth should be strongly inhibited within- about 24 hours. The growth of control cultures should be largely unaffected. a The synthetic oligonucieotide of the present indention may be mass produced according to common cloning techniques , such as those developed in the art to clone the gene for proinsuliπ. Alternatively, the oligo¬ nucieotide can be chemically synthesized in commercially 5 available equipment (described previously) . Briefly, the cloning method entails enzymatic insertion of tne oligo¬ nucieotide i nto a bacteri al gene carried on a l arger pi ece of DNA , known a s a pla smi d . Th e pl asm id c an be incorporated into a su itabl e hos t bacter ia , and multiple copies made as the bacteria mul tiply as in Boyer and Cohen , U. S. Patent No . 4 , 237 , 224. OMPI More particularly, and with reference to FIGS. 4 and 5, the cloning plasmid designated as pBR322, available from Bethesda Research Labs, Inc., Rockville, Maryland, can be used to mass produce the T protein specific oligonucieotide. Using standard techniques, the oligonucieotide is converted to double stranded form and then a terminal 5 'PO 4. is added to each of the 5' termini with polynucleotide kinase to permit subsequent joining through T-4 ligase. The reaction conditions for forming the 5' termini can be found in Richardson, Progress in Nucleic Acids Research 2 ^ :815 (1972). After purification of the double stranded oligonucieotide by chromatography on hydroxylapatite columns, it is inserted into the plasmid. Because the oligonucieotide is blunt ended, the plasmid should not have uneven or "sticky" ends. To remove sticky ends from the plasmid, SI nuclease or other single strand specific nucleases can be utilized. A general description of methods for using restriction nucleases can be found in Nathans and Smith, Annual Review of Biochemistry 44: 273 (1975) . For best results, a linker system between the oligonucieotide and the plasmid can be utilized, speci¬ fically a linker having both Hind III and Alu I enzymatic cleaving sites. As seen in FIG. 4, one such linker has a sequence: 5'... CTAAGCTTA.G...3 '. This sequence repre¬ sents a double stranded, .bisymmetric molecule containing a recognition sequence both for Alu I (AGCT) and for Hind III (AAGCTT) . Utilizing DNA ligase under standard conditions, this molecule can be ligated to the oligo¬ nucieotide to form linker-oligonucleotide-linker mole¬ cules. Similarly, the linked oligonucieotide can be introduced into linearized blunt-ended, Hind III cleaved • pBR322 carrier molecules. After ligation, the plasmid has resumed its ccvaϊently closed circular configuration with the linker- oligonucieotide incorporated, all of which is shown in FIG. 5 as pT-protein oligonucieotide. The recircularized plasmid is then used to transform a suitable bacterial host such as E. coli. The methods for transformation and selection -of transformants are known in the art and described in detail in Cohen and Beyer, U.S. Patent No. 4,237,224. Once the transformed bacteria containing the Iigated plasmid p-oligonucleotide have been grown to high density and produced large amounts of the Iigated plas- mid f the oligonuc.leotide is ready for purification-. After the plasmid has been removed from the mature cells, the plasmid is treated with appropriate restriction eπdoπucleases . As illustrated in FIG. 5, the plasmid is first cleaved with Hind III to give various by-products, including 1 inker-T-protein-oligonucleoti e-1 inker and fragmenc-3 Gf the original plasmid. These are readily separated utilizing gel electrophoresis or high pressure liquid chromotography. Further cleavage of the isolated liπker-oligonucleotide-l inker with the endonuclease Alu I yields pure double stranded oligonucieotide and partially degraded linker. These can also be separated based on their size differences. As shown in FIG. 6, the oligonucieotide can the;* be modified to a nuclease resistant phosphotriester form utilizing the reaction described in Miller et al, Biochemistry 16:1988 (1977). Basically, the oligonucleo- -^CffEA OMPI tide is first acylated using 50% acetic anhy ri e-pyri- dine during an overnight incubation period. The product is precipitated and isolated from ether. The phospho¬ triester can then be formed utilizing 30% ethanol in anydrous 2, 6 lutidene (30%) , NN-dimethyl formamide (30%) and p—toluene sulfonyl chloride (17%) , and reacting for about 6 hours. The protecting acetyl groups are then hydrolyzed by the addition of 0.5 volumes of concentrated ammonium hydroxide, followed by incubation for about 1 hour at 55 C. The final oligonucieotide product in the ethyl phosphotriester form can then be isolated on paper ch omotαgraphy or high pressure liquid chromotography. It is believed that transforming the oligo¬ nucieotide to a phosphotriester form will improve the oligonucieotide's stability _in ivo due to an enhanced resistance against, various degradative enzymes. However, the oligonucieotide will eventually degrade because of spontaneous de-ethylation, which leaves the molecule unprotected. Indeed, by controlling the initial level of ethylation, the iτι vivo degradation rate can be controlled. A further advantage of a phosphotriester form is believed to be an increase in the oligonucieo¬ tide's ability to penetrate a cell membrane. EXAMPLE 2 A synthetic oligonucieotide capable of inhibit¬ ing the synthesis of follicle stimulating hormone (FSH) , a protein hormone produced by the pituitary that func¬ tions in the maturation of ova in females and sperm cells - in males, can also be constructed. It is known that FSH is composed of two chains, alpha and beta, the amino acid sequence of which has been determined for several animal species. Interestingly, the alpha chain of FSH is common to? other gσnadotropic hormones, including thyroid stimu¬ lating hormone, luteinizing hormone, and chorionic gonadσtropin, while the beta chain varies. Therefore, to selectively shut off the synthesis of FSH without sub¬ stantially affecting the other gonadotropins, the oligo¬ nucieotide must be specific for the mRNA coding for the beta chain. The sequence of the beta chain amino acids 32 through 40 is shown in FIG. 7. As discussed earlier, it is possible tσ predict the mRNA base sequence for these amino acids, although not with absolute certainty. The points of uncertaint • are indicated by the letter "X" in the predicted mRNA sequence. Thus, the resultant oligo- nu leotide family consists of eight possible 26 base sequences; the potential alternate bases are shewn ia parentheses below the primary base sequence. By beginning with the projected mRNA sequence for the 33rd through 40th amino acids, it can be seen that four different 23 base oligonucleotides exist that could correspond to the FSH mRNA. The sequences could be as follows, reading from the 5' end: GTGTAGCAGTAGCCGGC- GCACCA, GTGTAGCAGTATCCGGCGCACCA, GTGTAGCAGTAGCCTGCGCACC , and GTGTAGCAGTATCCTGCGCACCA. One of these four sequences should be precisely correct and thus able to hybridize fully with the FSH mSfS - To determine the best sequence, a hybridization test against FSH mRNA,, with subsequent purification on hydroxylapatite or other suitable column, can be per- formed as previously described. Once the best sequence has been determined, it is placed in a plasmid or chemically synthesized, as described above, for bulk synthesis. This oligonucieotide should substantially inhibit the synthesis of FSH _in vivo. From the foregoing, it will be appreciated that the present invention provides a systematic method of designing new therapeutic agents for use in living organisms and that this method is versatile and inexpen¬ sive. Further, the oligonucieotide produced in accor¬ dance with the present invention is extremely effective and specific, enabling selective control of protein synthesis in a living organism. While several particular forms of the invention have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

Claims: CLAIMS . 1. A method of developing therapeutic agents comprising the steps of: providing a base sequence of an organism r s nucleic acid, said base sequence con¬ taining at least a portion of genetic information for a biological component of said organism; and synthesizing an oligonucieotide, the sequence of which is derived- - from said base sequence, for hybridization with messenger ribonucleic acid specific for said biological component. 2. The method of Claim 1 further including the step of: transforming said oligonucieotide into a more stable form to inhibit degradation by said organism. 3. The method of Claim 2 wherein said more stable form is a phosphotriester form. 4. The method of Claim 1 wherein said biological component is a protein. 5m The method of Claim.4 wherein said oligonucieotid is a deoxyribonucleotide. - 6. The method of Claim 1 wherein the base sequence comprises about fourteen or more bases. 7. The method of Claim 1 wherein the base sequence comprises about twenty-three bases. 8. The method of Claim 1 wherein the order of said base sequence is determined from ribonucleic acid or deoxyribonucleic acid specific for said biological component prior to synthesizing the oligonucieotide. 9 The method of Claim 1 further comprising the step σ : inserting said oligonucieotide into a plasmid for cloning. 10 -. The method of Claim 9 wherein said oligonucieoti is inserted into said plasmid with a linker base sequence. 11. The method of Claim 10 wherein said linker sequence is GATTCGAATC or CTAAGCTTAG. 12. The method of Claim 10 wherein the linker is susceptible to partial degradation by Hind III or alu I restriction nuclease. 13. The method of Claim 1 further comprising the -2 . 1- step of: cross-hybridizing the base sequence . against nucleic ' acid ' from at least one source other than said organism, whereby the base sequence is more specific to said organism. 14. A method of selectively controlling activity of one or more specific biological components in a cell without substantially interfering with the activity of other biological components of said cell, said method comprising the steps of: forming an oligonucieotide having a base sequence substantially complementary to a portion of messenger ribonucleic acid coding for said biological component; and introducing said oligonucieo¬ tide into said cell. 15. A method of inhibiting the infection of a host organism by a foreign organism, said method comprising the steps of: isolating a base sequence from said foreign organism's nucleic acid, the base sequence containing at least a portion of genetic information coding for a protein vital to said foreign . organism's viability; synthesizing an oligonucieotide, the order of which is ' derived from said base sequence to be substantially complementary to messenger ribonucleic aci . coding for the protein; and treating said foreign organism with an effective amount of cligonucleotide to hybridize with a portion of said messenger ribonucleic acid and block translation of said protein, thereby in¬ hibiting the viability of the foreign organism. 16. An agent for use in controlling synthesis of a protein, said agent comprising an oligonucieotide in a stabilized form to inhibit degradation and having a nucleotide sequence substantially complementary to a base sequence of at least a portion of messenger ribonucleic acid coding for said protein. OMPI " VJT O

Inventors: TULLIS RICHARD H, TULLIS, RICHARD, H.
Applicants: MOLECULAR BIOSYSTEMS INC, MOLECULAR BIOSYSTEMS, INC.
Application year: 1982
Main classification: C07H21
IPC codes: A01H1, A61K31, A61K35, A61K38, C07H1, C07H21, C12N5, C12N15, C12P19, C12P21, C12Q1, C12R1